stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) EPS (diluted)
Exelixis, Inc.'s EPS (diluted) for fiscal 2025 was $2.78, up 58.0% from $1.76 in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.34. Over the past ten years it has ranged from −$0.81 (fiscal 2015) to $2.78 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. Exelixis, Inc. ranks 17th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.78 | 57.95% |
| FY2024 | $1.76 | 170.77% |
| FY2023 | $0.65 | 16.07% |
| FY2022 | $0.56 | (22.22%) |
| FY2021 | $0.72 | 105.71% |
| FY2020 | $0.35 | (65.69%) |
| FY2019 | $1.02 | (53.85%) |
| FY2018 | $2.21 | 351.02% |
| FY2017 | $0.49 | — |
| FY2016 | −$0.28 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.85 | 3.66% |
| Jun 2026 | $0.82 | 3.80% |
| Mar 2026 | $0.79 | (10.23%) |
| Dec 2025 | $0.88 | 27.54% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $19.26 |
| ASND Ascendis Pharma A/S compare | $12.89 |
| HALO Halozyme Therapeutics, Inc. compare | $3.93 |
| EXEL Exelixis, Inc. | $3.34 |
| JAZZ Jazz Pharmaceuticals PLC compare | $2.95 |
| SMMT Summit Therapeutics PLC compare | −$1.12 |
| INSM Insmed, Inc. compare | −$2.82 |
| BBIO BridgeBio Pharma, Inc. compare | −$3.04 |
| BNTX BioNTech SE Sponsored ADR compare | −$6.85 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on EXEL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement